CD4 and neoplasm: Understanding these mechanisms of antigen priming and/or re-stimulation within the specific tumour microenvironments would be critical to harness the full potential of CD4+ T cells in cancer immunotherapy, and may inform rational combinations with therapies targeting antigen-presenting cells.